PMID- 21415973
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20211020
IS  - 2035-3006 (Electronic)
IS  - 2035-3006 (Linking)
VI  - 2
IP  - 2
DP  - 2010 Sep 7
TI  - Allogeneic transplantation for chronic lymphocytic leukemia.
PG  - e2010026
LID - 10.4084/MJHID.2010.026 [doi]
LID - e2010026
AB  - Even if Chronic lymphocytic leukemia (CLL) often has an indolent behavior with 
      good responsiveness to cytoreductive treatment, about 20% of the patients, so 
      called "poor-risk" patients, show an aggressive course and die within a few years 
      despite early intensive therapies. Criteria for poor-risk disease according to 
      the European Bone Marrow Transplantation (EBMT) CLL Transplant Consensus are: 
      purine analogue refractoriness, early relapse after purine analogue combination 
      therapy, CLL with p53 lesion requiring treatment.Allogeneic transplant has 
      potential curative role in CLL, however burden with very high transplant related 
      mortality (TRM) rates of 38-50%. A major advance in reducing the short-term 
      morbidity and mortality of allogeneic stem cell transplantation (SCT) has been 
      the introduction of non-myeloablative or reduced intensity conditioning (RIC) 
      regimens to allow engraftment of allogeneic stem cells. There is no doubt that 
      the crucial therapeutic principle of allo-SCT in CLL is graft versus leukemia 
      (GVL) activity.THE MAJOR COMPLICATIONS OF ALLOGENEIC SCT IN CLL ARE: chronic 
      graft-versus-host-disease (GVHD) affecting quality of life, high graft rejection 
      and infection rates correlated with preexisting immunosuppression. Disease 
      relapse remains the major cause of failure after RIC allo-HCT in CLL 
      patients.Sensitive minimal residual disease (MRD) quantification has strong 
      prognostic impact after transplant.
FAU - Laurenti, Luca
AU  - Laurenti L
AD  - Istituto di Ematologia, Policlinico "A. Gemelli", Universita' Cattolica del Sacro 
      Cuore, Rome, Italy.
FAU - Tarnani, Michela
AU  - Tarnani M
FAU - Chiusolo, Patrizia
AU  - Chiusolo P
FAU - Sora, Federica
AU  - Sora F
FAU - Sica, Simona
AU  - Sica S
LA  - eng
PT  - Journal Article
DEP - 20100907
PL  - Italy
TA  - Mediterr J Hematol Infect Dis
JT  - Mediterranean journal of hematology and infectious diseases
JID - 101530512
PMC - PMC3033136
EDAT- 2010/01/01 00:00
MHDA- 2010/01/01 00:01
PMCR- 2010/01/01
CRDT- 2011/03/19 06:00
PHST- 2010/07/13 00:00 [received]
PHST- 2010/08/08 00:00 [accepted]
PHST- 2011/03/19 06:00 [entrez]
PHST- 2010/01/01 00:00 [pubmed]
PHST- 2010/01/01 00:01 [medline]
PHST- 2010/01/01 00:00 [pmc-release]
AID - MJHID-2-2-e2010026 [pii]
AID - 10.4084/MJHID.2010.026 [doi]
PST - epublish
SO  - Mediterr J Hematol Infect Dis. 2010 Sep 7;2(2):e2010026. doi: 
      10.4084/MJHID.2010.026.